A Novel Small Molecule ITK Inhibitor Suppresses Th2/Th17 Differentiation and Attenuates Airway Inflammation in a Mouse Model of HDM ‐Induced Asthma
Immunology · 2025-11 · 176 (3) · 349-362
DOI: 10.1111/imm.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 12.06.2025. Verfasst von Zhaoxi Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Small Molecule Libraries, Protein-Tyrosine Kinases, Tyrosine Kinase Inhibitors, Th2 Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University.
Abstract (Originalsprache)
Interleukin (IL)‐2‐inducible T cell kinase (ITK) is essential for T cell receptor (TCR) signalling and plays a pivotal role in asthma pathogenesis. Thus, ITK inhibitors have therapeutic potential in T cell‐derived allergic airway inflammation. Nevertheless, no ITK inhibitors are currently approved for asthma treatment, warranting the need to excavate potent small‐molecule ITK inhibitors. Here, a novel small‐molecule ITK inhibitor C‐161 was discovered by compound screening. In silico docking and surface plasmon resonance (SPR) confirmed that C‐161 directly binds to the ITK kinase domain. In vitro cellular assays demonstrated that C‐161 prevents TCR‐induced proinflammatory cytokine release as well as activation and differentiation of Th2 and Th17 cells in a dose‐dependent manner. In vivo assays demonstrated that C‐161 administration ameliorates the progression of asthma by mitigating infiltration of inflammatory cells and decreasing mucus and IgE production. Additionally, C‐161 markedly suppressed airway inflammation by inhibiting Th2/Th17‐related immune responses with declined IL4, IL5, IL13 and IL17A expression. Collectively, our study uncovers a novel ITK‐specific small molecule inhibitor, C‐161, as an attractive lead compound for developing drugs to treat asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
- Huadong Research Institute for Medicine and Biotechniques, Nanjing, China.
ORCID-Profile: Juanjuan Zhu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Guo, Z., Ye, F., Zhang, Y., Xu, D., Shi, X., Wang, C., & Zhu, J. (2025). A Novel Small Molecule ITK Inhibitor Suppresses Th2/Th17 Differentiation and Attenuates Airway Inflammation in a Mouse Model of HDM ‐Induced Asthma. Immunology, 176(3), 349-362. https://doi.org/10.1111/imm.70003
Vancouver
Guo Z, Ye F, Zhang Y, Xu D, Shi X, Wang C, et al. A Novel Small Molecule ITK Inhibitor Suppresses Th2/Th17 Differentiation and Attenuates Airway Inflammation in a Mouse Model of HDM ‐Induced Asthma. Immunology. 2025;176(3):349-362. doi:10.1111/imm.70003
BibTeX
@article{Guo2025,
author = {Guo, Zhaoxi and Ye, Fuqiang and Zhang, Yongyou and Xu, Dong and Shi, Xuesong and Wang, Chen and Zhu, Juanjuan},
title = {A Novel Small Molecule ITK Inhibitor Suppresses Th2/Th17 Differentiation and Attenuates Airway Inflammation in a Mouse Model of HDM ‐Induced Asthma},
journal = {Immunology},
year = {2025},
volume = {176},
number = {3},
pages = {349--362},
doi = {10.1111/imm.70003}
}
EUVIMED